Código QR (código de barras bidimensional)

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma

Background Objective responses to immune checkpoint inhibitors (ICI) in leiomyosarcoma (LMS) are rare. Response rates may be increased by combination with other drugs known to promote immune infiltration, such as poly(ADP-ribose) polymerase (PARP) inhibitors, which have led to benefit in BRCA-altere...

ver descrição completa

Na minha lista:
Principais autores: Robert G Maki, Martina Bradic, Phillip Wong, William Tap, Vicky Makker, Sandra D’Angelo, Angela Green, Mrinal M Gounder, Evan Rosenbaum, Ciara M Kelly, Jason E Chan, Ping Chi, Mark A Dickson, Mary L Keohan, Sujana Movva, Viswatej Avutu, Martee L Hensley, Maria M Rubinstein, Ronak Shah, Kenneth Seier, Karmelina Charalambous, Seth M Cohen, Lauren B Banks, Sara Saunds, Jae-Mun Cho, Robert A Lefkowitz, Joseph Erinjeri, Li-Xuan Qin
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2025-06-01
coleção:Journal for ImmunoTherapy of Cancer
Acesso em linha:https://jitc.bmj.com/content/13/6/e012020.full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados